^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

threitolceramide 6 liposomal (PORT-2)

i
Other names: PORT-2, IMM60 liposomal, ThrCer6
Associations
Trials
Company:
Portage
Drug class:
iNKT agonist
Associations
Trials
7ms
KEYNOTE-E69: IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
P1/2; Trial completion date: Dec 2026 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Apr 2024; Prioritization of other pipeline assets. No safety or efficacy issues were observed.
Trial completion date • Trial primary completion date • Trial termination • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)
10ms
KEYNOTE-E69: IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
P1/2; Recruiting --> Active, not recruiting | N=100 --> 1
Enrollment change • Enrollment closed • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)
1year
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • BRAF mutation • PD-L1 negative
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)
almost2years
IMM60 and Pembrolizumab in Melanoma and NSCLC (clinicaltrials.gov)
P1/2; N=100; Not yet recruiting; Sponsor:iOx Therapeutics
New P1/2 trial • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • BRAF mutation • PD-L1 negative
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • threitolceramide 6 liposomal (PORT-2)